Related references
Note: Only part of the references are listed.Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia
Meletios Athanasios Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of Biologicals in the Treatment of Rheumatoid Arthritis A Meta-Analysis
S. P. Venkateshan et al.
PHARMACOLOGY (2009)
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Gilles Salles et al.
BLOOD (2008)
Use of rituximab in diffuse large B-cell lymphoma in the salvage setting
Christian Gisselbrecht
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases
Manuel Ramos-Casals et al.
MEDICINE (2008)
Therapeutic Potential for B-Cell Modulation in Sjogren's Syndrome
Xavier Mariette
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2008)
Anti-CD20 treatment in Primary Sjogren's Syndrome
K. Isaksen et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2008)
Targeted treatment and new agents in diffuse large B-cell lymphoma
John P. Leonard et al.
SEMINARS IN HEMATOLOGY (2008)
CD74: A new candidate target for the immunotherapy of B-Cell neoplasms
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2007)
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab
Josette Carnahan et al.
MOLECULAR IMMUNOLOGY (2007)
Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab
Rhona Stein et al.
BLOOD (2006)
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study
Juergen Rech et al.
LEUKEMIA & LYMPHOMA (2006)
The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined Immunodeficient mice
C Carlo-Stella et al.
CANCER RESEARCH (2006)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
R Stein et al.
CLINICAL CANCER RESEARCH (2004)
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
AP Mone et al.
BLOOD (2004)
Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma
M Altomonte et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies
R Stein et al.
BLOOD (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
In vivo pharmacodynamic effects of Hu1D10 (Remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells
JD Shi et al.
LEUKEMIA & LYMPHOMA (2002)
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma
JW Friedberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated fas and activation of caspases
V Blancheteau et al.
HUMAN IMMUNOLOGY (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Complement activation plays a key role in the side-effects of rituximab treatment
LE van der Kolk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
B Bellosillo et al.
BLOOD (2001)
The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds
J Schuurman et al.
MOLECULAR IMMUNOLOGY (2001)
Share Paper
